8-KLeadership Changes

JOHNSON & JOHNSON 8-K Report, Executive Changes (Feb 21, 2012)

Filed February 21, 2012For Securities:JNJ

Summary

Johnson & Johnson announced significant leadership changes via an 8-K filing on February 21, 2012. The most impactful news for investors is the appointment of Alex Gorsky as the new Chief Executive Officer (CEO), effective April 26, 2012. This transition marks a succession plan where current Chairman and CEO William C. Weldon will step down from his CEO role but remain as Chairman of the Board. This move signals a new chapter for the company under Gorsky's leadership. Alex Gorsky, with extensive experience within Johnson & Johnson across various divisions including Medical Devices and Pharmaceuticals, as well as a prior stint at Novartis, brings a deep understanding of the company's operations. His appointment to CEO and expected nomination to the Board of Directors indicate a strategic vision likely focused on continued growth and operational integration. Investors should monitor Gorsky's initial strategic directives and the ongoing role of Weldon as Chairman.

Key Highlights

  • 1Alex Gorsky appointed as the new Chief Executive Officer (CEO), effective April 26, 2012.
  • 2William C. Weldon will transition from CEO to Chairman of the Board, effective April 26, 2012.
  • 3Alex Gorsky will be nominated for election to the Board of Directors at the 2012 Annual Meeting of Shareholders.
  • 4Gorsky's annual base salary will increase to $1,200,000 in connection with his CEO appointment.
  • 5The filing includes a press release dated February 21, 2012, announcing these leadership changes.
  • 6Gorsky has a strong background within JNJ, holding various leadership positions since 1988 and returning in 2008 after a period at Novartis.

Frequently Asked Questions

Alex Gorsky has been appointed as the new Chief Executive Officer (CEO) of Johnson & Johnson. This change is effective April 26, 2012.

William C. Weldon, who is currently Chairman and CEO, will relinquish the CEO position on April 26, 2012, and will continue to serve as the Chairman of the Board of Directors.

Alex Gorsky has a long history with Johnson & Johnson, originally joining in 1988. He has held numerous leadership roles across various segments including Pharmaceuticals and Medical Devices. After a period at Novartis, he returned to JNJ in 2008 and has been a Vice Chairman of the Executive Committee since January 2011.

Yes, Alex Gorsky will be nominated for election to the Board of Directors of Johnson & Johnson at the 2012 Annual Meeting of Shareholders.